The Investment Column: JJB is still goal-orientated, but investors say it's a long-ball game, not a quick net result

Alizyme; Premier Oil

Our view: Sell

Share price: 124.25p (-3p)

Wigan Athletic football club, which is sponsored by retailer JJB Sports, narrowly avoided relegation from the premiership this season. Sadly for JJB, the team is about the only thing that is not going down.

At an initial glance, there is very little in JJB to commend to investors. Sales were down 8 per cent in the 13 weeks to the end of April, according to yesterday's trading update; revenues were down 8.3 per cent.

On a valuation basis, things do not look much better. According to analysts at Dresdner Kleinwort, JJB trades at 14 times estimated 2009 earnings, which is a premium to a host of retail stocks including Clinton Cards, Halfords and Mothercare. The group's gearing is so high that a 1 per cent change in sales leads to a 10 per cent move in operating profit. In short, things are not looking that great, particularly as most observers reckon that the country's economic problems are not going away any time soon.

All bad news, then? Well, not so fast. Yes, the group is toiling and investors would be crazy to buy the stock hoping for an immediate return. But the analysts at Dresdner still have the group at hold, saying that the potential recovery story is good. The group has closed loss-making stores, especially in areas where the company has out-of-town shops and is trying to avoid being an entirely retail entity by opening a series of health centres. Furthermore, JJB, which has previously relied on the major summer football tournaments to sell replica shirts, is trying to rid itself of that model, which is just as well given that England will be conspicuous by its absence from this summer's European championships.

Investors should also be buoyed by the fact that the group is 22.3 per cent owned by Icelandic fund Exista, and while they are not expected to launch a takeover bid, the holding should provide a backstop against the shares falling through the floor.

The recovery story is good. But recovery has not started yet and analysts are still complaining about a lack of visibility. JJB might be a solid, longer-term punt, but not for now. Sell.


Our view: Buy

Share price: 26.5p (-1.5p)

For biotech firms to go from a being a small scientific organisation to a successful pharmaceutical group (or more likely, be bought up a pharma giant) they need some of their ideas to succeed. And that is why the stock was sent spiralling on news in April that Alizyme's treatment for irritable bowel syndrome, Renzapride, had failed its phase-three trial.

The group's shares have been on a downward trajectory since, after hitting year highs of 105p last June. However, observers are not as downbeat as you might expect. True, those at Investec, who revised their price target from 41p to 59p on the bad Renzapride news, say that given where the shares trade, the stock is theoretically a hold.

However, the analysts advise clients to buy the stock. The reason is the group's other potential blockbuster, the anti-obesity and type 2 diabetes drug Celilistat, which is expected to win "a major licensing deal... in the near future. We therefore recommend buying on weakness", they say.

Finn Capital points out that the group has raised £10m from institutional lenders to remain a going concern and, "this demonstrates institutional confidence in Alizyme's ability to deliver", they reckon.

The truth is that buying into smaller biotech companies is always a punt. Those with a nervous disposition should avoid the sector that depends largely on companies with sound ideas transforming good science into a commercially viable treatment. The failure list is long.

However, while analysts are all too happy to point out a basket case when they see one, none ascribes that moniker to Alizyme, which is also set to receive third phase results on another treatment, Colal-Pred, for ulcerative colitis, in July.

Biotech valuations are largely driven by news flow. Alizyme is expecting lots in the next few months, and most of it is likely to be good. Buy.

Premier Oil

Our view: Buy

Share price: 1738p (-9o)

Back in March, The Investment Column suggested that buyers should back Premier Oil at 1343p. And despite the jump in the stock since then, investors would still be well-advised to get more.

With the black stuff at almost $130 a barrel and rising, most oil companies are doing well. Tullow Oil's shares jumped massively a couple of weeks ago on news that it had confirmed a major new find off Ghana.

The same could well be about to happen to Premier Oil. In a trading update, the group yesterday revised its target of 50,000 barrels a day (bpd) to 80,000 bpd by 2012, saying that its exploration activities in Vietnam, in an area where the group has done well in the past, were on course.

Analysts at Evolution Securities, who are in the process of upgrading their estimates, say that a strong news flow, coupled with the high oil price, will drive the stock up. The group, they say is still cheap compared to the sector, which includes companies such as Tullow and Cairn Energy. Buy.

Start your day with The Independent, sign up for daily news emails
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Digital Optimisation Executive - Marketing

£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...

Recruitment Genius: Financial Reporting Manager

£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...

Recruitment Genius: Payments Operations Assistant

£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...

Recruitment Genius: Telephone Debt Negotiator

£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...

Day In a Page

Syria civil war: Meet the military commander who says his soldiers will not rest until every inch of their war torn country is free of Islamist 'terrorists'

‘We won’t stop until Syria is back to normal’

Near the front lines with Islamist-controlled towns where Assad’s troops were besieged just last month, Robert Fisk meets a commander confidently preparing his soldiers for battle
The inside story of how Bill Clinton built a $2bn global foundation may undermine Hillary's chances

The inside story of how Bill Clinton built a $2bn global foundation...

... and how it may undermine Hillary's chances in 2016
12 best olive oils

Extra-virgin, cold-press, early-harvest, ultra-premium: 12 best olive oils

Choosing an olive oil is a surprising minefield. Save yourself the hassle with our handy guide
Sepp Blatter resignation: The beginning of Fifa's long road to reform?

Does Blatter's departure mean Fifa will automatically clean up its act?

Don't bet on it, says Tom Peck
Charles Kennedy: The baby of the House who grew into a Lib Dem giant

The baby of the House who grew into a Lib Dem giant

Charles Kennedy was consistently a man of the centre-left, dedicated to social justice, but was also a champion of liberty and an opponent of the nanny-state, says Baroness Williams
Syria civil war: The harrowing testament of a five-year-old victim of this endless conflict

The harrowing testament of a five-year-old victim of Syria's endless civil war

Sahar Qanbar lost her mother and brother as civilians and government soldiers fought side by side after being surrounded by brutal Islamist fighters. Robert Fisk visited her
The future of songwriting: How streaming is changing everything we know about making music

The future of songwriting

How streaming is changing everything we know about making music
William Shemin and Henry Johnson: Jewish and black soldiers receive World War I Medal of Honor amid claims of discrimination

Recognition at long last

Jewish and black soldiers who fought in WWI finally receive medals after claims of discrimination
Beating obesity: The new pacemaker which helps over-eaters

Beating obesity

The new pacemaker which helps over-eaters
9 best women's festival waterproofs

Ready for rain: 9 best women's festival waterproofs

These are the macs to keep your denim dry and your hair frizz-free(ish)
Cycling World Hour Record: Nervous Sir Bradley Wiggins ready for pain as he prepares to go distance

Wiggins worried

Nervous Sir Bradley ready for pain as he prepares to attempt cycling's World Hour Record
Liverpool close in on Milner signing

Liverpool close in on Milner signing

Reds baulk at Christian Benteke £32.5m release clause
On your feet! Spending at least two hours a day standing reduces the risk of heart attacks, cancer and diabetes, according to new research

On your feet!

Spending half the day standing 'reduces risk of heart attacks and cancer'
With scores of surgeries closing, what hope is there for the David Cameron's promise of 5,000 more GPs and a 24/7 NHS?

The big NHS question

Why are there so few new GPs when so many want to study medicine?
Big knickers are back: Thongs ain't what they used to be

Thongs ain't what they used to be

Big knickers are back